Skip to content

The effect of HBF2019-02 on lipid metabolism

The effect of HBF2019-02 on lipid metabolism - The effect of HBF2019-02 on lipid metabolism

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000037835
Enrollment
22
Registered
2019-09-16
Start date
2019-09-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

Sponsors

Oneness Support Co., Ltd
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: (1) Healthy adult men (2) LDL-Cho from 120 to 139 mg / dL or LDL-Cho from 140 to 159 mg / dL (3) Subjects who can make self-judgment and are voluntarily giving written informed consent.

Exclusion criteria

Exclusion criteria: (1) Subjects with hepatic, renal, cardiac and/or organ disorders, diabetes, and/or other serious diseases. (2) Subjects with abnormal liver and kidney function test values. (3) Subjects with a disease currently being treated. (4) Subjects with food and drug allergies. (5) Subjects with anemia. (6) Subjects who play intense sports and subjects who are on a diet. (7) Subjects who cannot refrain from taking health foods (including certain health foods and functionally labeled foods) and designated quasi drugs during the test period. (8) Those who continue to take medicines (including OTC and prescription drugs). (9) Those who consume excessive alcohol, or who cannot ban alcohol from the day before the test to the day. (10) Participants in or planning to participate in other clinical studies at the start of this study. (11) Subjects who judged as unsuitable for this study by the principal investigator for any reasons.

Design outcomes

Primary

MeasureTime frame
Lipid metabolism related indicators

Secondary

MeasureTime frame
Physical examination, and medical examination by hematology, blood biochemistry, urinalysis

Countries

Japan

Contacts

Public ContactChiyo Yoshizane

Hayashibara CO., LTD. R&D Division, Development Unit

chiyo.yoshizane@hb.nagase.co.jp086-276-3141

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026